IS5379A - Efnasambönd með taugafrumuvirkni - Google Patents

Efnasambönd með taugafrumuvirkni

Info

Publication number
IS5379A
IS5379A IS5379A IS5379A IS5379A IS 5379 A IS5379 A IS 5379A IS 5379 A IS5379 A IS 5379A IS 5379 A IS5379 A IS 5379A IS 5379 A IS5379 A IS 5379A
Authority
IS
Iceland
Prior art keywords
compounds
neuronal activity
neuronal
activity
Prior art date
Application number
IS5379A
Other languages
English (en)
Icelandic (is)
Inventor
Mccaffrey Patricia
M. Novak Perry
Mullican Michael
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/085,441 external-priority patent/US6268384B1/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of IS5379A publication Critical patent/IS5379A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5379A 1997-08-29 2000-02-18 Efnasambönd með taugafrumuvirkni IS5379A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92083897A 1997-08-29 1997-08-29
US09/085,441 US6268384B1 (en) 1997-08-29 1998-05-27 Compounds possessing neuronal activity
PCT/US1998/017816 WO1999010340A1 (en) 1997-08-29 1998-08-27 Compounds possessing neuronal activity

Publications (1)

Publication Number Publication Date
IS5379A true IS5379A (is) 2000-02-18

Family

ID=26772724

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5379A IS5379A (is) 1997-08-29 2000-02-18 Efnasambönd með taugafrumuvirkni

Country Status (17)

Country Link
US (1) US7109215B2 (OSRAM)
EP (1) EP1007521A1 (OSRAM)
JP (1) JP2001514177A (OSRAM)
CN (1) CN100436447C (OSRAM)
AU (1) AU766579B2 (OSRAM)
BR (1) BR9811923A (OSRAM)
CA (1) CA2300134A1 (OSRAM)
ID (1) ID23675A (OSRAM)
IL (1) IL134536A0 (OSRAM)
IN (1) IN191127B (OSRAM)
IS (1) IS5379A (OSRAM)
NO (1) NO321790B1 (OSRAM)
NZ (1) NZ502820A (OSRAM)
PL (1) PL195273B1 (OSRAM)
SG (1) SG129998A1 (OSRAM)
TW (1) TW570919B (OSRAM)
WO (1) WO1999010340A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
EP1084106A1 (en) * 1998-06-03 2001-03-21 GPI NIL Holdings, Inc. N-linked sulfonamides of heterocyclic carboxylic acids or carboxylic acid isosteres
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
EP1196387A1 (en) 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Azo amino acid derivatives for the treatment of neurological diseases
EP1196385A1 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Beta-amino acid derivatives for the treatment of neurological diseases
WO2001002368A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity
WO2001008685A1 (en) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
AU6076000A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Cyclic amine derivatives for the treatment of neurological diseases
AU6913700A (en) * 1999-08-18 2001-03-13 Schering Aktiengesellschaft Piperidine and pyrrolidine derivatives displaying neuronal activity
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
EP1244670B1 (en) 1999-12-21 2006-03-08 MGI GP, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
JP2002068973A (ja) * 2000-06-16 2002-03-08 Meiji Milk Prod Co Ltd 幹細胞分化誘導促進剤
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2004031148A1 (en) * 2002-10-03 2004-04-15 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment of neurological diseases
WO2005033068A1 (en) * 2003-10-06 2005-04-14 Oy Juvantia Pharma Ltd Somatostatin receptor 1 and/or 4 selective agonists and antagonists
EP1720564A1 (en) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
WO2007088479A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
EP2114436A1 (en) * 2006-12-20 2009-11-11 Rinat Neuroscience Corp. Trkb agonists for treating autoimmune disorders
US9152929B2 (en) 2013-01-23 2015-10-06 Splunk Inc. Real time display of statistics and values for selected regular expressions
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
MX9202466A (es) * 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5686469A (en) * 1993-02-09 1997-11-11 Miles Inc. Aminomethylene derivaties as immunosuppressants
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds

Also Published As

Publication number Publication date
US20020013351A1 (en) 2002-01-31
NO20000953L (no) 2000-05-02
ID23675A (id) 2000-05-11
AU8923698A (en) 1999-03-16
WO1999010340A1 (en) 1999-03-04
AU766579B2 (en) 2003-10-16
SG129998A1 (en) 2007-03-20
PL338791A1 (en) 2000-11-20
CN1271354A (zh) 2000-10-25
PL195273B1 (pl) 2007-08-31
BR9811923A (pt) 2000-08-15
CA2300134A1 (en) 1999-03-04
JP2001514177A (ja) 2001-09-11
IL134536A0 (en) 2001-04-30
IN191127B (OSRAM) 2003-09-27
NZ502820A (en) 2002-10-25
TW570919B (en) 2004-01-11
NO321790B1 (no) 2006-07-03
EP1007521A1 (en) 2000-06-14
CN100436447C (zh) 2008-11-26
NO20000953D0 (no) 2000-02-25
US7109215B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
IS5379A (is) Efnasambönd með taugafrumuvirkni
PT973746E (pt) 3-ciano-quinolinas substituidas
DE69801567D1 (de) Polyisocyanataerogel
ID24529A (id) Turunan-turunan 9-oksima eritromisin
NO980340L (no) Fluidoverföringssystem
DE59808569D1 (de) Fräsbrecherfahrzeug
ZA987478B (en) Compounds possessing neuronal activity
DE59801498D1 (de) Dioxacycloalkan-8-one
DE59808447D1 (de) Kabelhalter
DE69811218D1 (de) Tongeber
DE59806790D1 (de) Acrylesterkautschukpartikel
DE69702094D1 (de) N-Acetonylbenzamidverbindungen mit fungizider Aktivität
DE69720185T2 (de) Verdunsterkarussell
PT1020448E (pt) Aril-heterociclos com actividade herbicida
DK1019042T3 (da) Forbindelser med anti-første-passagevirkning
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
FI972138A0 (fi) Returtraog i bestrykningsanordning
DE59809000D1 (de) Strassenhalmkasten
ITMI981551A1 (it) Fenilazoaniline
BR9701194A (pt) Hidrociclo
BR7700990U (pt) Gaiolas
UA2208S (uk) Інкубатор
SE9703419D0 (sv) Arrangemang
FI971651A0 (fi) Spaormaskin i en elmaskin
FI974373A0 (fi) Avgasutlopp i utombordsmotorer